Clinical Trials

Current Clinical Research Projects

PEARSON PA, Blackburn PJ, Yunker JJ, Higgins EB.  A pilot study of the safety and efficacy of 0.2 µg/day Iluvien™ (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg in subjects with macular edema secondary to retinal vein occlusion. C-01-08-006.  Alimera Sciences, Inc.

Blackburn PJ, Pearson PA, Higgins EB.  C-01-11-008:  An Open Label, Multi-center Extension Study of the Safety and Utility of the New Inserter  of ILUVIEN® (Fluocinolone Acetonide Intravitreal Insert) 0.19 mg and the Safety of ILUVIEN in Subjects with Diabetic Macular Edema.  Alimera Sciences, Inc. 

Pearson PA, Blackburn PJ, Higgins EB. Open-Label Pilot Safety Study of AP-104IVT (Sustained-Release Fluticasone, Intravitreal) after a Single Intravitreal Injection in Patients with Macular Edema.  Auritec Pharmaceutical, Inc.

Kleinman ME, Blackburn PJ, Higgins EB, Fraser CE, Thompson KG.  A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects with Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye.  PSV-FAI-001.  pSivida Corp.

Effect of Corneal Preservation Time on Long-Term Graft Success  Cornea Preservation Time Study (CPTS) Dr. Woodford Van Meter.  Case Western University.

The Association of Cytokines in the Two Clinical Subtypes of Ophthalmic Graves’ Disease
Dr. Peter Timoney.  University of Kansas Medical Center.

A Phase I, open-label, dose escalation study to evaluate the safety and tolerability of Latanoprost sustained release (SR) insert in patients with primary open angle glaucoma (POAG) or ocular hypertension (OH)
Dr. Shelia Sanders.  pSivida.